Option chain shows key data for iShares Ethereum Trust - iShares Ethereum Trust ETF's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for iShares Ethereum Trust - iShares Ethereum Trust ETF.

iShares Ethereum Trust - iShares Ethereum Trust ETF (NASDAQ:ETHA) Stock, Option Chain

What Happened

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Markets

General

$DOGE

ETHA

IBIT

Editor’s Note: This story has been updated with a response from a Bitwise spokesperson.

Bets Favoring Dogecoin ETF Approval In 2025 Jump After Bitwise&#39;s Delaware Filing—Top Trader Paints Over 4000% Upside For Memecoin (UPDATED)

Bitcoin and Ethereum Photo by Marisha on Shutterstock

Sector ETFs

ETFs

$BTC

$ETH

ARK 21Shares Bitcoin ETF ARK 21Shares Bitcoin ETF

ARKB

Bitwise Bitcoin ETF Common Shares of Beneficial Interest

BITB

ETHV

Fidelity Wise Origin Bitcoin Fund Fidelity Wise Origin Bitcoin Fund

FBTC

Fidelity Ethereum Fund Fidelity Ethereum Fund

FETH

Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) spot ETFs registered inflows of $3.26 billion and $74.43 million, respectively, over the past four days.

Bitcoin, Ethereum ETFs Attract Record Inflows Despite Market Volatility, Policy Uncertainty

Bitcoin ETF

$SOL

$USDC

$XRP

Bitcoin and Ethereum spot ETFs experienced a significant resurgence on Jan. 15, with a combined net inflow of over $815 million, marking the first positive day after a four-day outflow period.

Bitcoin Consolidates Around $99,000 After $750 Million ETF Inflows On Wednesday

iShares Ethereum Trust - iShares Ethereum Trust ETF

Ethan Allen Interiors Inc

<a href="https://www.globenewswire.com/Tracker?data=HvsFSj6wlccOf1GJMazWUp_UC0bGpV7nEP94bhMBZcldNWL0rkVJJztxNngjOaEnD7GdIpPOsLosm_8Tti7HxqtiC_Czc0CqvfoZuSAokpI=">Purple Biotech Ltd.</a> ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today that it has entered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai ("Icahn School of Medicine") in New York, NY, to explore the immunoregulation of NK and T cells within the TME by Purple's CAPTN-3 multi-specific engagers with the purpose of enhancing tumor-specific immunity against various cancer types.

PPBT

Purple Biotech Teams Up with Mount Sinai to Boost Cancer Immunotherapy Research

Coverage from one of the largest payors in the country expands access to fetal RhD testing for pregnant patients nationwide

NTRA

Natera Gains National Commercial Coverage For Fetal RhD NIPT, Expanding Access To Noninvasive Prenatal Testing

Entrada Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.

Government

Regulations

TRDA

Entrada Therapeutics Gets UK Approval to Launch Phase 1/2 Trial for Duchenne Muscular Dystrophy Treatment

D. Boral Capital analyst Jesse Sobelson initiates coverage on Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Buy rating and announces Price Target of $4.5.

Price Target

Initiation

Analyst Ratings

VERI

D. Boral Capital Initiates Coverage On Veritone with Buy Rating, Announces Price Target of $4.5

The Quantum Realized brand campaign will span digital and print advertising channels, and events, including D-Wave's annual user conference, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.qubits.com%2F&amp;esheet=54197513&amp;newsitemid=20250203660061&amp;lan=en-US&amp;anchor=Qubits+2025&amp;index=2&amp;md5=e2080bc36adfb360e0e709997ab99aaf">Qubits 2025</a>, and the Company's sponsorship of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fquantum2025.org%2F&amp;esheet=54197513&amp;newsitemid=20250203660061&amp;lan=en-US&amp;anchor=International+Year+of+Quantum+Science+and+Technology&amp;index=3&amp;md5=4fa22edee833a73483f848e7d1fba67c">International Year of Quantum Science and Technology</a>, an initiative that aims to raise public awareness about quantum computing.
 &nbsp;

QBTS

D-Wave Quantum Launches New Integrated Brand Campaign, "Quantum Realized," To Showcase  Benefits Of Quantum Computing

President Donald Trump's tariffs have sparked a backlash within the mining sector, given the deeply intertwined trade relationship between the U.S. and Canada. The Mining Association of Canada (MAC) warned that these measures could disrupt critical mineral supply chains and <a target="_blank" href="https://www.benzinga.com/topic/u-s-economy" rel="noreferrer noopener">harm both economies</a>.
"Canada has long been a dependable partner, providing certainty to U.S. manufacturing and defense industries by serving as a major supplier of minerals and metals," <a target="_blank" href="https://www.newswire.ca/news-releases/mining-association-of-canada-responds-to-us-tariff-action-against-canada-859859664.html" rel="noreferrer noopener">said</a> Pierre Gratton, MAC president and CEO. "The imposition of tariffs on Canadian minerals and metals runs counter to American national security and economic interests."
In 2022, over half of Canada's mineral exports, valued at more than $80 billion, went to the U.S. These exports included critical minerals such as nickel, uranium, and aluminum, essential for U.S. industries, including defense, technology, and renewable energy. The tariffs threaten to strain these supply chains, increase costs for U.S. manufacturers, and push Canada to seek alternative markets.
One of the most significant examples of U.S.-Canada interdependence is the Red Dog Mine in Alaska. This mine, operated by Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>), is the world's largest zinc mine and a notable producer of germanium—a critical mineral used in fiber optics, computer chips, and night-vision equipment. However, before these materials reach U.S. manufacturers, they are refined in Canada, primarily at Teck Resources' smelter in Trail, British Columbia.
"The cross-border nature of that supply chain means that it will be heavily impacted," Gracelin Baskaran, a mining economist at the Center for Strategic and International Studies, <a target="_blank" href="https://alaskabeacon.com/2025/01/31/a-major-alaska-mine-could-end-up-in-the-crossfire-of-trumps-trade-war-with-canada/" rel="noreferrer noopener">said</a> for Alaska Beacon. Nearly 89% of Canada's germanium exports go to the U.S., making it a vital buffer against supply disruptions.
In response to the tariffs, Canada has announced retaliatory measures, including 25% levies on U.S. imports such as beer, wine, and bourbon. Prime Minister Justin Trudeau warned that these tariffs would harm U.S. consumers and industries, <a target="_blank" href="https://www.cbc.ca/news/politics/trudeau-speech-trump-tariffs-1.7448540" rel="noreferrer noopener">stating</a>, "They will impede your access to an affordable supply of vital goods crucial for U.S. security, such as nickel, potash, uranium, steel, and aluminum."
Thus, in a trade war scenario, the zinc and germanium from Red Dog could face double fees: once when exported to Canada for refining and again when the refined products return to the U.S.
"Instead of tariffs, Canada and the U.S. should be focusing on deepening collaboration," Gratton said. He also called on Canadian governments to address domestic challenges, such as regulatory inefficiencies and uncompetitive tax policies, to improve the sector's competitiveness.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/econ-s/25/01/43348204/gold-hits-record-high-as-central-banks-ease-stance-5-mining-stocks-rally" target="_blank" rel="noreferrer noopener">Gold Hits Record High As Central Banks Ease Stance: 5 Mining Stocks Rally</a></li>
</ul>
Photo by Feng Yu via Shutterstock

Commodities

Politics

TECK

Miners Plead For Collaboration As Trade Wars Threaten Critical Mineral Supply Chains

FS Investments is one of Philadelphia's fastest growing companies and is helping Philadelphia reestablish its reputation as a home to leading financial services firms. With over $83 billion in assets under management and nearly 600 employees, the firm's continued growth drove the need for more space. Brandywine's West Tower in Schuylkill Yards offered FS state-of-the-art facilities, modern amenities that support attracting top talent and easy access to Amtrak's William H. Gray III 30th Street Station, facilitating seamless travel between FS' headquarters and its second and third largest offices in Connecticut and New York, respectively.

FS Investments Selects Schuylkill Yards For New Global Headquarters In 117,000 Sq. Ft., 16-Year Lease With Brandywine Realty Trust

<a href="https://www.globenewswire.com/Tracker?data=z0AWl3tJoSIUl76KC4vUVUAzdm1l2rsX7LsixFW855l2-sT40eG8RxNmqZMlS5i3Qp494Ylft9o_TKMdGS0ctQ==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the completion of enrollment in the first cohort of the Phase I/IIa trial of AMT-191, an investigational gene therapy for the treatment of Fabry disease. Additionally, the Independent Data Monitoring Committee (IDMC) reviewed safety data from the initial two patients enrolled in the first cohort. The IDMC's review identified no significant safety concerns and recommended proceeding with enrollment in the second cohort.

QURE

uniQure Completes First Cohort Enrollment in Gene Therapy Trial for Fabry Disease, Safety Review Clears Path for Next Phase

The study will enroll an initial cohort of six end-stage renal disease (ESRD) patients, expanding to up to 50 participants, and is intended to support a Biologics License Application (BLA) with the FDA.
United Therapeutics expects the first xenotransplant in this trial to be performed around mid-year 2025.

UTHR

United Therapeutics Says Cleared Its Investigational New Drug Application To Initiate Clinical Study Of Investigational UKidney Derived From 10 Gene-edited Source Pig

GH Research PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click <a href="https://www.globenewswire.com/Tracker?data=zilQbQ-pRm32KGXr9YhLxnvOjS4Gqju5_BA26n3NbRn1kqI15MbnzExAXSt_uStmwkWSaDmEITYKk13arupB7LFICTLHRyZnbAphhCZ3r2o=">here</a>.
The trial recruited 81 patients with TRD. In the double-blind part, 40 patients received GH001 and 41 received placebo. Psychotherapeutic intervention was not a component of either part of this trial.
GH001 led to a significant reduction from baseline of -15.2 points in Montgomery-Åsberg Depression Rating Scale (MADRS) total score on Day 8, compared with +0.3 points in the placebo group (difference of -15.5 points, p&lt;0.0001).
All secondary endpoints in the trial were met, with results consistent with the primary endpoint. Treatment with GH001 led to clinically and statistically significant improvements on the CGI-S and HAM-A scales and the Q-LES-Q-SF Questionnaire on Day 8, compared with placebo.

GHRS

GH Research's Inhalable Depression Treatment GH001 Hits Primary Endpoint in Phase 2b Trial, Showing Symptom Reduction

<h3>Gainers</h3>
<ul>
<li>Algorhythm Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIME#NASDAQ">RIME</a>) shares moved upwards by 12.9% to $0.03 during Monday's pre-market session. The market value of their outstanding shares is at $2.7 million. </li>
<li>U Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCAR#NASDAQ">UCAR</a>) stock moved upwards by 10.78% to $2.98. The company's market cap stands at $11.9 million. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCTM#NASDAQ">TCTM</a>) stock rose 8.38% to $0.84. The company's market cap stands at $8.3 million. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) stock rose 7.55% to $1.85. The market value of their outstanding shares is at $63.8 million. </li>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock rose 6.22% to $0.45. The market value of their outstanding shares is at $6.6 million. </li>
<li>Raytech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAY#NASDAQ">RAY</a>) shares moved upwards by 5.85% to $1.27. The market value of their outstanding shares is at $22.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Envirotech Vehicles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVTV#NASDAQ">EVTV</a>) stock declined by 26.7% to $0.33 during Monday's pre-market session. The company's market cap stands at $5.3 million. </li>
<li>Culp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CULP#NYSE">CULP</a>) shares declined by 17.63% to $4.44. The company's market cap stands at $55.7 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) stock declined by 15.66% to $0.17. The market value of their outstanding shares is at $45.4 million. </li>
<li>Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) stock declined by 14.59% to $6.03. The company's market cap stands at $631.6 million. </li>
<li>Nxu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXU#NASDAQ">NXU</a>) shares decreased by 12.43% to $0.26. The market value of their outstanding shares is at $6.2 million. </li>
<li>Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) shares fell 10.99% to $1.62. The company's market cap stands at $186.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CLEU

CULP

CURV

EVTV

GDHG

NRDY

RIME

TCTM

UCAR

VEEE

12 Consumer Discretionary Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 27.4% to $13.5 during Monday's pre-market session. The market value of their outstanding shares is at $702.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 25.08% to $0.35. The market value of their outstanding shares is at $15.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 23.0% to $0.44. The market value of their outstanding shares is at $52.6 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 21.95% to $0.32. The market value of their outstanding shares is at $9.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 15.06% to $0.47. The company's market cap stands at $4.0 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock rose 14.29% to $0.49. The company's market cap stands at $9.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares fell 45.3% to $0.08 during Monday's pre-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares fell 16.29% to $4.01. The company's market cap stands at $232.1 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 14.79% to $4.15. The company's market cap stands at $57.2 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 14.38% to $2.74. The market value of their outstanding shares is at $72.2 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock fell 13.17% to $5.87. The market value of their outstanding shares is at $113.4 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) stock fell 12.22% to $4.6. The market value of their outstanding shares is at $173.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ANVS

CUTR

HCWB

ICAD

IVVD

NVCT

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PRPH

VIRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Air Industries Group a leading manufacturer of precision components and assemblies for large aerospace and defense prime contractors, today announced that its primary lender, Webster Bank has amended the terms of its Credit Facility. Relaxing the required Covenants, permitting the repayment of Subordinated Debt, and expanding the Company's Term Loan by approximately $1.6 million. These funds will be used for the purchase of new state of the art machinery, costing approximately $1.9 million. This investment in production equipment will support the recently announced $33 million contract and will greatly increase throughput.

AIRI

Air Industries Expands Term Loan With Webster Bank To Fund New Machinery For CH-53K Helicopter Production

<h3>Gainers</h3>
<ul>
<li>Triumph Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGI#NYSE">TGI</a>) shares moved upwards by 34.7% to $25.25 during Monday's pre-market session. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Air Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIRI#AMEX">AIRI</a>) shares moved upwards by 17.66% to $5.13. The market value of their outstanding shares is at $17.2 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares rose 13.65% to $1.29. The market value of their outstanding shares is at $20.3 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares moved upwards by 11.92% to $0.68. The market value of their outstanding shares is at $10.1 million. </li>
<li>Antelope Ent Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHL#NASDAQ">AEHL</a>) shares rose 7.62% to $0.13. The company's market cap stands at $4.2 million. </li>
<li>Mynaric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYNA#NASDAQ">MYNA</a>) stock moved upwards by 6.31% to $0.47. The market value of their outstanding shares is at $11.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) shares declined by 40.6% to $0.54 during Monday's pre-market session. The market value of their outstanding shares is at $24.0 million. </li>
<li>Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) stock fell 10.07% to $435.5. The company's market cap stands at $17.5 billion. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares fell 9.95% to $0.54. The market value of their outstanding shares is at $42.9 million. </li>
<li>Sentage Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTG#NASDAQ">SNTG</a>) shares decreased by 9.9% to $1.73. The company's market cap stands at $4.8 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) stock fell 9.41% to $0.44. The company's market cap stands at $12.8 million. </li>
<li>KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>) stock decreased by 8.66% to $1.9. The market value of their outstanding shares is at $454.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHL

KULR

LGCL

MYNA

OMEX

PITA

SNTG

ZBAI

12 Industrials Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares rose 17.8% to $14.81 during Monday's pre-market session. The company's market cap stands at $3.5 billion. </li>
<li>MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) shares rose 8.14% to $4.38. The market value of their outstanding shares is at $162.9 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock moved upwards by 6.97% to $0.29. The market value of their outstanding shares is at $7.4 million. </li>
<li>Aurora Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JG#NASDAQ">JG</a>) shares rose 6.53% to $8.31. The market value of their outstanding shares is at $49.7 million. </li>
<li>Roadzen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDZN#NASDAQ">RDZN</a>) stock rose 6.25% to $1.53. The market value of their outstanding shares is at $113.5 million. </li>
<li>Zebra Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) stock increased by 5.4% to $413.14. The market value of their outstanding shares is at $21.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares fell 47.1% to $0.14 during Monday's pre-market session. The market value of their outstanding shares is at $3.0 million. </li>
<li>Vislink Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VISL#NASDAQ">VISL</a>) stock fell 21.43% to $2.2. The company's market cap stands at $5.4 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNHP#NASDAQ">SLNHP</a>) stock declined by 15.3% to $7.7. </li>
<li>Foxx Development Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXX#NASDAQ">FOXX</a>) shares decreased by 12.67% to $5.45. The company's market cap stands at $39.6 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) shares decreased by 12.44% to $3.31. The company's market cap stands at $1.9 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) stock declined by 11.3% to $1.03. The company's market cap stands at $66.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FOXX

RDZN

SLNHP

TDTH

VISL

ZBRA

12 Information Technology Stocks Moving In Monday's Pre-Market Session

Apogee Therapeutics, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&amp;I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis (EoE) and other I&amp;I indications, today announced the first patient has been dosed in the Part B portion of the Phase 2 APEX clinical trial of APG777 in patients with moderate-to-severe AD, as well as enrollment completion in the Part A portion of the trial.

APGE

Apogee Therapeutics Doses First Patient in Phase 2 Trial for APG777, Advancing Treatment for Moderate-to-Severe Atopic Dermatitis

Wells Fargo analyst Ike Boruchow downgrades PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from Overweight to Equal-Weight and lowers the price target from $130 to $105.

Downgrades

Wells Fargo Downgrades PVH to Equal-Weight, Lowers Price Target to $105

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com%2F&amp;esheet=54197454&amp;newsitemid=20250203957122&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=57559066139c4e5dbfbbca31156a600f">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new policy for commercial coverage of its cfDNA Fetal RhD noninvasive prenatal test (Fetal RhD NIPT) from one of the largest payors in the United States.
Effective as of Jan. 2025, the policy notes that coverage of fetal RhD testing is available when a pregnancy may be at risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy.
Up to 15 percent of pregnant patients are RhD-negative1. When the maternal blood type is RhD-negative and the fetal blood type is RhD-positive, antibodies can develop (alloimmunization) that can lead to hemolytic disease of the fetus and newborn.
Natera's Fetal RhD NIPT can be performed as early as nine weeks gestation and determines fetal RhD status from the blood of a pregnant patient. It is offered through the Company's women's health suite of products, which includes Panorama, the no. 1 ordered NIPT in the U.S.

Natera Secures Insurance Coverage for Fetal RhD Noninvasive Prenatal Test, Expanding Access for High-Risk Pregnancies

B of A Securities analyst Ross Fowler downgrades American States Water (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWR#NYSE">AWR</a>) from Neutral to Underperform and lowers the price target from $85 to $71.

B of A Securities Downgrades American States Water to Underperform, Lowers Price Target to $71

It is payable on March 3, 2025, to shareholders of record as of February 14, 2025.&nbsp;

Comments

iShares Ethereum Trust - iShares Ethereum Trust ETF

iShares Ethereum Trust - iShares Ethereum Trust ETF (ETHA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga